Outcomes of Acinetobacter baumannii infection in critically ill burned patients

Journal of Burn Care and Research

Volumn 28, Issue 2, 2007, Pages 248-254

  Trottier, Vincent ^a   Segura, Penelope Gonzalez ^b   Namias, Nicholas ^a,c   King, David ^a   Pizano, Louis R ^a   Schulman, Carl I ^a  

^a JACKSON MEMORIAL HOSPITAL   (United States)

^b INTEC University   (Dominican Republic)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; COLISTIN; IMIPENEM; MINOCYCLINE;

ACINETOBACTER BAUMANNII; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; BACTERIUM ISOLATE; BURN; BURN INFECTION; BURN UNIT; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DOSAGE SCHEDULE COMPARISON; FEMALE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LUNG LAVAGE; MALE; MORTALITY; SEX RATIO; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; AGED; AMIKACIN; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIURIA; BRONCHOALVEOLAR LAVAGE FLUID; BURN UNITS; BURNS; CATHETERIZATION, CENTRAL VENOUS; COLISTIN; CRITICAL ILLNESS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FLORIDA; HUMANS; IMIPENEM; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33947164142     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0B013E318031A20F     Document Type: Article

References (45)

1. Pruitt BA, McManus AT. The changing epidemiology of infection in burn patients. World J Surg 1992;16:57-67.
2. Wurtz R, Karajovic M, Dacumos E, et al. Nosocomial infections in a burn intensive care unit. Burns 1995;21:181-4.
3. Lee JJ, Marvin JA, Heimbach DM, et al. Infection control in a burn center. J Burn Care Rehabil 1990;11:575-80.
4. Weber JM, Tompkins DM. Improving survival: infection control and burns. AACN Clin Issues Crit Care Nurs 1993;4:414-23.
5. Law EJ, Blecher K, Still JM. Enterococcal infections as a cause of mortality and morbidity in patients with burns. J Burn Care Rehabil 1994;15:236-9.
6. Dickama DJ, and the SENTY Participants Group. Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. Int J Antimicrob Ag 2000;13:257-71.
7. Jarvis WR, Martone WJ. Predominant pathogens in hospital infections. J Antimicrob Chemother 1992;29(Suppl A):19-24.
8. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) study. EPIC International Advisory Committee. JAMA 1995;274:639-44.
9. Paul M, Weinberger M, Siegman-Igra Y, et al. Acinetobacter baumannii: emergence and spread in Israeli hospitals 1997-2002. J Hosp Infect 2005;60:256-60.
10. Minnangati VR, Cunha BA. Acinetobacter baumannii-associated arterial line infection. Am J Infect Control 2000;28:376-7.
11. Hanberger J, and the French and Portuguese ICU Study Group. Antibiotic susceptibility among aerobic gram-negative bacilli in ICU in 5 European countries. JAMA 1999;28:67-70.
12. King D, Namias N, Pizano LR, et al. An unusual cause of septicemia and death in a burn patient: discussion and review. J Burn Care Rehabil 2005;26:502-4.
13. Bergogne-Berezin E. The increasing significance of outbreaks of Acinetobacter spp.: the need for control and new agents. J Hosp Infect 1995;30(Suppl):441-52.
14. Schreckenberger PC, von Gravevenitz A. Acinetobacter, Alcaligenes, Moraxella, Methylobacterium, and other nonfermentative gram-negative rods. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of clinical microbiology. Washington: ASM Press; 1999. p. 539-60.
15. Lyytikainen O, Koljalg S, Harma M, et al. Outbreak caused by two multi-resistant Acinetobacter baumannii clones in a burn unit: emergence of resistance to imipenem. J Hosp Infect 1995;31:41-54.
16. Roberts SA, Findlay R, Lang SDR. Investigation of an outbreak of multi-drug resistant Acinetobacter baumannii in an intensive care burns unit. J Hosp Infect 2001;48:228-32.
17. Bergogne-Berezin E, Joly-Guillon ML, Vieu JF. Epidemiology of nosocomial infections due to Acinetobacter calcoaceticus. J Hosp Infect 1987;10:105-13.
18. Getchell-White SI, Donowitz LG, Groschel DHM. The inanimate environment of an intensive care unit as a source of nosocomial bacteria: evidence for long survival of Acinetobacter calcoaceticus. Infect Control Hosp Epidemiol 1989;10:402-7.
19. Cefai C, Richards J, Gould FK, et al. An outbreak of Acinetobacter respiratory tract infection, resulting from incomplete disinfection of ventilatory equipment. J Hosp Infect 1990;5:177-82.
20. Santucci SG, Gobara S, Santos CR, et al. Infections in a burn intensive care unit : experience of seven years. J Hosp Infect 2003;53:6-13.
21. Lortholary O, Fagon JY, Hoi AB, et al. Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clin Infect Dis 1995;20:790-6.
22. Peacock JE, Sorrell L, Sottile FD, et al. Nosocomial respiratory tract colonization and infection with aminoglycoside-resistant Acinetobacter calcoaceticus var. anitratus: epidemiologic characteristics and clinical significance. Infect Control Hosp Epidemiol 1998;9:302-8.
23. Mulin B, Talon D, Viel JF, et al. Risk factors for nosocomial colonization with multiresistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 1995;14:569-76.
24. Scerpella EG, Wanger AR, Armitige L, et al. Nosocomial outbreak caused by a multiresistant clone of Acinetobacter baumannii: results of the case-control and molecular epidemiologic investigation. Infect Control Hosp Epidemiol 1995;16:92-7.
25. Vandenbroucke-Grauls CM, Kerver AJ, Rommes JH, et al. Endemic Acinetobacter anitratus in a surgical intensive care unit : mechanical ventilators as reservoirs. Eur J Clin Microbiol Infect Dis 1998;7:485-9.
26. French GL, Casewell MW, Roncoroni AJ, et al. A hospital outbreak of antibiotic-resistant Acinetobacter anitratus: epidemiology and control. F Hosp Infect 1980;1:125-31.
27. Bergogne-Berezin E, Joly-Guillou ML. An underestimated nosocomial pathogen, Acinetobacter calcoaceticus. F Antimicrob Chemother 1985;16:535-8.
28. Glew RH, Moellering RC, Kunz LJ. Infections with Acinetobacter calcoaceticus (Herellea vaginicola). Clinical and laboratory studies. Medicine 1977;56:79-87.
29. Weinbren MJ, Johnson AP, Kaufmann ME. Acinetobacter spp. isolates with reduced susceptibility to carbapenems in a U.K. burns unit. J Antimicrob Chemother 1998;41:474-6.
30. LeFloch R, Arnould JF, Pilorget A. Effect of systematic empiric treatment with imipenem on the bacterial ecology in a burns unit. Burns 2005;31:866-9.
31. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez J, et al. Treatment of multidrug resistant Acinetobacter baumannii ventilator associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003;36:1111-8.
32. Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-11.
33. Michalopoulos A, Kasiakou SK, Mastora Z, et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005;9:R53-59.
34. Kwa ALH, Low CS, Low JGH, et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005;41:754-7.
35. Berlana D, Llop JM, Fort E, et al. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health-Syst Pharm 2005;62:39-47.
36. Michalopoulos AS, Tsiodras S, Rellos K, et al. Colistin treatment in patients with ICU-acquired infections caused by multiresistant gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005;11:115-21.
37. Reina R, Estenssoro E, Saenz G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 2005;31:1058-65.
38. Montero A, Ariza J, Corbella X, et al. Efficacy of colistin versus β-lactams, aminoglycosides and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002;46:1946-52.
39. Michalopoulos A, Kasiakou SK, Mastora Z, et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005;9:R53-9.
40. Bradford PA, Weaver-Sands T, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structures infections and complicated intra-abdominal infections. Clin Infect Dis 2005;41:S315-332.
41. Bang RL, Gang RK, Sanyal SC, et al. Burn septicaemia: an anlysis of 79 patients. Burns 1998;24:354-61.
42. Sengupta S, Kumar P, Ciraj AM, et al. Acinetobacter baumannii - an emerging nosocomial pathogen in the burns unit Manipal, India. Burns 2001;27:140-4.
43. Wisplinghoff H, Perbix W, Seifert H. Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: a case-control study of adult burn patients. Clin Infect Dis 1999;28:59-66.
44. Wilson SJ, Knipe CJ, Zieger MJ, et al. Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital. Am J Infect Control 2004;32:342-4.
45. Wong TH, Tan BH, Ling ML, et al. Multi-resistant Acinetobacter baumannii on a burns unit - clinical risk factors and prognosis. Burns 2002;28:349-57.